Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $23,563 | 8 | 92.8% |
| Unspecified | $1,771 | 5 | 7.0% |
| Food and Beverage | $59.07 | 2 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SpringWorks Therapeutics, Inc. | $15,985 | 4 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $7,637 | 6 | $0 (2024) |
| F. Hoffmann-La Roche AG | $1,771 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,851 | 10 | SpringWorks Therapeutics, Inc. ($15,985) |
| 2023 | $1,860 | 2 | Alexion Pharmaceuticals, Inc. ($1,860) |
| 2022 | $2,681 | 3 | Alexion Pharmaceuticals, Inc. ($2,469) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | SpringWorks Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| 12/13/2024 | SpringWorks Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 12/13/2024 | SpringWorks Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 11/18/2024 | Alexion Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,470.00 | General |
| 11/14/2024 | SpringWorks Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $13,060.00 | General |
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $411.63 | Research |
| Study: Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $411.63 | Research |
| Study: Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $398.49 | Research |
| Study: Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $336.43 | Research |
| Study: Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children | ||||||
| 01/10/2024 | Alexion Pharmaceuticals, Inc. | KOSELUGO (Drug) | Consulting Fee | Cash or cash equivalent | $1,837.50 | General |
| Category: Oncology | ||||||
| 06/25/2023 | Alexion Pharmaceuticals, Inc. | KOSELUGO (Drug) | Food and Beverage | In-kind items and services | $30.37 | General |
| Category: Oncology | ||||||
| 01/17/2023 | Alexion Pharmaceuticals, Inc. | KOSELUGO (Drug) | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| Category: Oncology | ||||||
| 11/09/2022 | Alexion Pharmaceuticals, Inc. | KOSELUGO (Drug) | Consulting Fee | Cash or cash equivalent | $2,440.00 | General |
| Category: Oncology | ||||||
| 06/19/2022 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $28.70 | General |
| 03/31/2022 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $212.68 | Research |
| Study: A PHASE 11B, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB RXDX-101 IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS, WITH OR WITHOUT TRK, ROS1, OR ALK FUSIONS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Open Label Dose Escalation and Expansion Study of Entrectinib RXDX 101 in Children | F. Hoffmann-La Roche AG | $1,558 | 4 |
| A PHASE 11B, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB RXDX-101 IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AND PRIMARY CNS TUMORS, WITH OR WITHOUT TRK, ROS1, OR ALK FUSIONS | F. Hoffmann-La Roche AG | $212.68 | 1 |
About Dr. Amy Armstrong, MD
Dr. Amy Armstrong, MD is a Pediatrics healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2012. The National Provider Identifier (NPI) number assigned to this provider is 1487917951.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amy Armstrong, MD has received a total of $25,392 in payments from pharmaceutical and medical device companies, with $20,851 received in 2024. These payments were reported across 15 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($23,563).
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Hematology-Oncology
- Location Saint Louis, MO
- Active Since 06/20/2012
- Last Updated 04/15/2025
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1487917951
Products in Payments
- KOSELUGO (Drug) $6,138
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Saint Louis
Dr. Philip Spinella, Md, MD
Pediatrics — Payments: $286,187
Dr. David Balzer, Md, MD
Pediatrics — Payments: $209,718
Dr. Amy Clark, Do, DO
Pediatrics — Payments: $129,192
Dr. Jennifer Silva, Md, MD
Pediatrics — Payments: $128,336
Dr. Nico Dosenbach, Md, MD
Pediatrics — Payments: $115,400
Dr. Kel Vin Woo, M.d., Ph.d, M.D., PH.D
Pediatrics — Payments: $100,017